



Revance Therapeutics  
Investor Relations Department  
7555 Gateway Boulevard  
Newark, CA 94560  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: RVNC

Last Trade:	26.95
Trade Time:	4:00 PM ET Oct 16, 2017
Change:	0.20  (+0.748%)
Day Range	26.60 - 27.30
52-Week Range	12.35 - 28.75
Volume	75,257


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which, when combined with active drug molecules, may help address current unmet needs.

Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthe... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

Sep 19, 2017

[Revance to Participate in the Cantor Fitzgerald 2017 Global Healthcare Conference](#)

Sep 6, 2017

[Revance Appoints Mark Foley to its Board of Directors](#)

Aug 30, 2017

[Revance to Participate in the 2017 Wells Fargo Securities Healthcare Conference](#)

Aug 3, 2017

[Revance Releases Second Quarter 2017 Results](#)

Aug 2, 2017

[Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics](#)

## Financials [\[ View all \]](#)

[Second Quarter Financial Results](#)

Feb 28, 2017

[Annual Report \(10-K\)](#)

Mar 24, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 4, 2017

[Quarterly Report \(10-Q\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)

Nov 4, 2016

[Quarterly Report \(10-Q\)](#)